EU Regulators Move to Streamline Oversight of Combination Products

EU Regulators Move to Streamline Oversight of Combination Products

The regulatory environment for medical devices and pharmaceuticals is currently navigating a pivotal transformation as stakeholders strive to bridge the gap between two traditionally distinct oversight frameworks. The lack of a clear legal definition for combination products has historically created uncertainty, which the new pharmaceutical legislation seeks to finally resolve. At the recent 2026 Combination Products Summit in Baltimore, a gathering of prominent European regulators and industry specialists highlighted the urgent need to modernize the oversight of products that integrate medicinal components with advanced delivery systems. As these technologies become increasingly sophisticated, incorporating features like digital connectivity and high-precision dosing, previous regulatory silos are proving inadequate for the speed of modern innovation. This shift represents a broader effort to refine Article 117 of the Medical Device Regulation, aiming to reduce the administrative burden on manufacturers while ensuring that patient safety remains the paramount concern. Through a more cohesive approach, the European Union is setting the stage for a streamlined marketing authorization process that accommodates the unique characteristics of drug-device combinations.

Strengthening Cooperation and Efficiency

Shifting Responsibilities: The Evolution of Article 117

Under the current framework of the Medical Device Regulation, there has been a marked departure from previous assessment methodologies regarding integral drug-device combination products. Historically, national health authorities managed the majority of technical evaluations for well-established delivery mechanisms, such as prefilled syringes and basic injection pens. However, the maturation of the MDR has shifted a significant portion of this responsibility toward Notified Bodies, which are now tasked with providing formal opinions on the device components of these medicinal products. This transition acknowledges that modern delivery systems are no longer simple containers but complex engineering feats that require specialized technical scrutiny. By delegating the device-specific review to these expert bodies, regulators are attempting to ensure that every mechanical and electrical aspect of a combination product undergoes a rigorous certification process that is independent of the pharmaceutical evaluation. This expert-led scrutiny is vital for maintaining the high safety standards expected by patients and clinicians throughout the region as delivery technologies continue to advance.

Integrating these specialized opinions into the broader marketing authorization process remains a primary objective for European regulators aiming to streamline the approval pathway. The goal is to ensure that the technical assessment provided by a Notified Body serves as a robust foundation for the European Medicines Agency during its final evaluation of the product’s safety and efficacy profile. As delivery systems evolve to include complex functionalities—such as biometric sensors or integrated electronics—the “notified body opinion” must be delivered in a format that seamlessly supports the medicinal assessment rather than creating redundant work or conflicting requirements. Regulators are focused on refining this intersection to prevent bottlenecks that could delay patient access to life-saving therapies. Achieving this requires a clear understanding of where device expertise ends and pharmaceutical oversight begins, creating a balanced and highly efficient review ecosystem for innovators. This streamlined coordination is expected to reduce the time-to-market for products that offer significant clinical improvements over existing standard-of-care delivery methods.

Strategic Integration: The Impact of the COMBO Group

One of the most promising developments in the current landscape is the emergence of multi-stakeholder collaboration driven by the Combination Products Operational Group, commonly referred to as COMBO. This organization acts as a central hub for communication, bringing together the European Medicines Agency, the European Commission, and various national competent authorities from across the continent. By creating a formalized venue for discussion, COMBO facilitates a unified dialogue that was previously absent in the European regulatory sphere. This collaboration is essential for navigating the inherent complexities of products that do not fit neatly into a single regulatory category. The group’s work involves identifying potential roadblocks in the certification process and developing consensus-based solutions that can be applied consistently across all member states. This initiative represents a fundamental shift away from isolated regulatory assessments toward a more holistic view of product oversight. By involving all relevant parties in the decision-making process, the COMBO group ensures that the regulatory path is both predictable and scientifically sound for all developers.

The establishment of the COMBO group has already begun to yield tangible benefits by clarifying the so-called “gray areas” that frequently arise during the classification of novel technologies. As manufacturers develop increasingly creative solutions that blur the lines between drugs and devices, the need for a harmonized interpretation of existing rules becomes critical for maintaining market stability. Through the collaborative efforts of this group, the European regulatory system is maturing into a more predictable and transparent environment for all stakeholders involved. This maturity is reflected in the group’s ability to coordinate between the Notified Body Coordination Group and medicines competent authorities, ensuring that policies are not developed in a vacuum. The focus remains on building a resilient framework that can adapt to the rapid pace of medical advancement while reducing the risk of conflicting guidance from different regional authorities. This unified front is key to making the European market attractive for global developers who seek a clear and consistent regulatory pathway for their most innovative and complex product candidates.

Future-Proofing: Legal Definitions and AI Integration

The ongoing revision of European pharmaceutical legislation presents a unique opportunity to establish robust legal definitions that cater specifically to the nuances of combination products. Historically, the absence of a dedicated legal category has led to classification disputes and confusion regarding which set of rules takes precedence during the authorization phase. By codifying these definitions into law, the EU provides the foundational certainty that industry players need to justify long-term investments in research and development. This legislative clarity is particularly important as the industry moves toward highly integrated systems where the drug and the device are inseparable in both function and marketing. Parallel to these legislative updates, the regulation of Artificial Intelligence within medical devices has become a focal point, ensuring that evaluations remain grounded in medical-specific risks and clinical performance metrics rather than being subject to the broader EU AI Act. This strategic decision ensures that the unique safety considerations of healthcare technology are managed by experts.

The 2026 summit successfully established a roadmap for the future of combination product oversight by emphasizing the power of direct engagement and transparency. Industry representatives and regulators agreed that fostering a culture of face-to-face interaction was the most effective way to demystify complex requirements and build mutual trust. It was concluded that the immediate focus should shift toward the finalization of harmonized templates and the implementation of pilot programs for the proposed structured dialogue. Stakeholders emphasized that manufacturers must take the initiative by conducting thorough internal gap analyses against the new definitions to ensure their portfolios remain compliant. Furthermore, the development of robust data-sharing protocols between Notified Bodies was identified as a critical next step to prevent the duplication of effort in the assessment of common components. These collective actions represented a decisive step toward a more agile and responsive regulatory framework in the European Union, ultimately benefiting patients through faster access to innovation.

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later